Landiolol

Brand names: Rapiblyk · Active ingredient: Landiolol Hydrochloride

In short: RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter, and pediatric patients with supraventricular tachycardia.

Forms & strengthsFor injection: White to almost white lyophilized powder in a single-dose vial containing 280 mg of landiolol (equivalent to 300 mg landiolol HCl).
LabelAOP Orphan Pharmaceuticals GmbH
Label updatedNov 03, 2026

What is Landiolol used for?

RAPIBLYK is indicated for the short-term reduction of ventricular rate in

adults with supraventricular tachycardia including atrial fibrillation and atrial flutter, and

pediatric patients with supraventricular tachycardia.

Landiolol dosage

Administer RAPIBLYK as a continuous intravenous infusion in a monitored setting, titrating as needed for heart rate control. There are limited data beyond 24 hours of use.

Adults | Pediatric patients

Normal cardiac function | Impaired cardiac function | Normal cardiac function*

Starting dose | 9 mcg/kg/min | 1 mcg/kg/min | 9 mcg/kg/min

Titration interval | 10 min | 15 min | 10 min

Titration step | 9 mcg/kg/min | 1 mcg/kg/min | 9 mcg/kg/min

Maximum dose | 36 mcg/kg/min | 36 mcg/kg/min | 36 mcg/kg/min

*There are no data to guide dosage recommendations in pediatric patients with impaired cardiac function.

When transitioning to alternative medications consider the pharmacodynamics of the medication to which the patient is being transitioned and monitor clinical response. If switched to an oral beta-blocker, the dosage of RAPIBLYK can be reduced as follows:

Ten minutes after administration of the oral beta-blocker, reduce the infusion rate of RAPIBLYK by 50%.

If satisfactory control is maintained for at least one hour, discontinue RAPIBLYK.

Use appropriate aseptic technique for reconstitution.

Reconstitute each 280 mg vial of RAPIBLYK with 50 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Gently swirl to dissolve contents.

Inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit. The reconstituted solution should be a clear, colorless solution.

Use immediately. The reconstituted RAPIBLYK solution storage conditions are described in Table 2.

Discard unused portion.

Diluent used to Prepare Solution | Reconstituted RAPIBLYK Solution Storage and Use Conditions

50 mL of 0.9% Sodium Chloride Injection, USP | Use within 4 hours at room temperature (25°C, 77°F)

50 mL of 5% Dextrose Injection, USP | Use within 48 hours at room temperature (25°C, 77°F)

Following reconstitution, the product contains 280 mg landiolol/50 mL = 5.6 mg/mL.

The infusion rate can be calculated as:

Infusion rate (mL/hour) = target dose (mcg/kg/min) × body weight (kg) / 93

Warnings & precautions

Do not take this medicine if: RAPIBLYK is contraindicated in patients with:

Severe sinus bradycardia, sick sinus syndrome, heart block greater than first degree

.

Decompensated heart failure

.

Cardiogenic shock: May precipitate further cardiovascular collapse and cause cardiac arrest.

Pulmonary hypertension: May precipitate cardiorespiratory decompensation.

Hypersensitivity reactions, including anaphylaxis, to landiolol or any of the inactive ingredients

Patients with hemodynamic compromise, hypovolemia, or on interacting medications are at increased risk of hypotension. Monitor blood pressure closely, especially if pretreatment blood pressure is low. Reduce or stop RAPIBLYK injection for hypotension then expect the blood pressure effect to wane within 30 minutes.

Patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders are at increased risk of bradycardia, including sinus pause, heart block, severe bradycardia, and cardiac arrest. Monitor heart rate and rhythm in patients receiving RAPIBLYK injection. Reduce or stop RAPIBLYK injection for bradyarrhythmia.

Beta-blockers, like RAPIBLYK, can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock. At the first sign or symptom of impending cardiac failure, stop RAPIBLYK injection and start supportive therapy

.

Patients with reactive airways disease should, in general, not receive beta-blockers. Because of its relative beta-1 selectivity and titratability, RAPIBLYK injection may be titrated to the lowest possible effective dose. In the event of bronchospasm, stop the infusion immediately; a beta-2 stimulating agent may be administered with appropriate monitoring of ventricular rates. …

Landiolol side effects

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of RAPIBLYK was evaluated in 19 placebo-controlled clinical trials involving 1,761 adult patients (in a variety of clinical in-patient settings) with supraventricular tachycardia or at high risk for supraventricular tachycardia. The most common adverse reaction is hypotension, which occurred in 9.9% of patients receiving RAPIBLYK vs. 1% in those receiving placebo .

In a single-arm, unblinded clinical trial in 60 pediatric patients who received RAPIBLYK, the most common adverse reaction was hypotension, which occurred in 10% of patients aged birth to <18 years receiving RAPIBLYK . Hypotension was also the most common adverse reaction leading to treatment discontinuation.

Drug interactions

Avoid concomitant use of RAPIBLYK with negative inotropes and medications that slow heart rate or cardiac conduction.

Beta-blockers, like RAPIBLYK, can cause depression of myocardial contractility and increase the risk of bradycardia or heart block. Concomitant use of RAPIBLYK with negative inotropes or chronotropes may augment these effects

.

Beta adrenergic agonists will antagonize the effects of RAPIBLYK and may attenuate the heart rate lowering effects of RAPIBLYK. Positive inotropes and vasoconstrictors may attenuate the heart rate and blood pressure lowering effects of RAPIBLYK.

Observe patients treated with RAPIBLYK plus a catecholamine depletor (e.g., reserpine, monoamine oxidase inhibitors) for hypotension or marked bradycardia, which may cause vertigo, syncope, or postural hypotension.

Catecholamine depleting drugs may have an additive effect when given with beta-blockers, which may increase the risk of hypotension or marked bradycardia related vertigo, syncope, or postural hypotension

.

About this medicine

RAPIBLYK (landiolol) for injection is a beta-1 adrenergic receptor blocker with a very short duration of action (elimination half-life is approximately 4 minutes). Landiolol is:

[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propionate and has the following structure:

The active pharmaceutical ingredient is the hydrochloride salt of landiolol, which has the empirical formula C

25H

39N

3O

8 ∙ HCl and a molecular weight of 546.06 g/mol. It has two chiral centers and is used as pure S,S-enantiomer.

Landiolol HCl is a white crystalline powder. It is a relatively hydrophilic compound, which is very soluble in water.

RAPIBLYK is supplied as a single presentation of 280 mg landiolol (equivalent to 300 mg landiolol HCl) as a white to almost white sterile lyophilized powder for intravenous injection in a single-dose vial. Inactive ingredients include 300 mg of mannitol and sodium hydroxide as needed to adjust pH. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 27e7f20f-78a4-f1a9-e063-6394a90ae465. Read the full official label on DailyMed.

Related medicines

Rosuvastatin Semaglutide Hydrochlorothiazide Apixaban Simvastatin Empagliflozin Furosemide Carvedilol